Immunoadsorption to treat patients with severe post-COVID syndrome.

IF 1.5 4区医学 Q3 HEMATOLOGY

Therapeutic Apheresis and Dialysis Pub Date : 2023-08-01 DOI:10.1111/1744-9987.13974

Benjamin Giszas, Philipp A Reuken, Katrin Katzer, Michael Kiehntopf, Diana Schmerler, Silke Rummler, Andreas Stallmach, Anne Klink

{"title":"Immunoadsorption to treat patients with severe post-COVID syndrome.","authors":"Benjamin Giszas, Philipp A Reuken, Katrin Katzer, Michael Kiehntopf, Diana Schmerler, Silke Rummler, Andreas Stallmach, Anne Klink","doi":"10.1111/1744-9987.13974","DOIUrl":null,"url":null,"abstract":"Introduction: Following SARS-CoV-2-infection up to 21% of patients will develop post-COVID-syndrome. Autoantibodies (AAbs) targeting neuronal-ß-adrenergic and muscarinic receptors may provide crucial contributions to the pathophysiology of this condition. Immunoadsorption (IA) has been identified as an effective means of removing AAbs and has resulted in clinical improvements of other autoantibody-associated diseases.Methods: We determined AAb-levels (anti-ß1/ß2 and anti-M3/M4 receptor) in 178 patients diagnosed with post-COVID-syndrome and described the clinical courses of two patients with elevated AAb-levels that underwent IA-treatment.Results: AAbs were detected in 57% (101/178) of patients diagnosed with post-COVID-syndrome. Substantial reductions in AAb-levels and clinical remission were achieved in one of two patients who was treated with IA. However, this patient relapsed within 6 weeks with a concomitant increase in AAb-levels.Conclusion: Collectively, AAbs may play a pathophysiologic role in post-COVID and their removal provide transient benefits in some patients. However, these findings should be further investigated in randomized-controlled-trials.","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Apheresis and Dialysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1744-9987.13974","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Introduction: Following SARS-CoV-2-infection up to 21% of patients will develop post-COVID-syndrome. Autoantibodies (AAbs) targeting neuronal-ß-adrenergic and muscarinic receptors may provide crucial contributions to the pathophysiology of this condition. Immunoadsorption (IA) has been identified as an effective means of removing AAbs and has resulted in clinical improvements of other autoantibody-associated diseases.

Methods: We determined AAb-levels (anti-ß1/ß2 and anti-M3/M4 receptor) in 178 patients diagnosed with post-COVID-syndrome and described the clinical courses of two patients with elevated AAb-levels that underwent IA-treatment.

Results: AAbs were detected in 57% (101/178) of patients diagnosed with post-COVID-syndrome. Substantial reductions in AAb-levels and clinical remission were achieved in one of two patients who was treated with IA. However, this patient relapsed within 6 weeks with a concomitant increase in AAb-levels.

Conclusion: Collectively, AAbs may play a pathophysiologic role in post-COVID and their removal provide transient benefits in some patients. However, these findings should be further investigated in randomized-controlled-trials.

查看原文本刊更多论文

免疫吸附治疗重症后冠状病毒综合征

在sars - cov -2感染后，高达21%的患者会出现后冠状病毒综合征。针对神经元-ß-肾上腺素能受体和毒蕈碱受体的自身抗体(AAbs)可能对这种疾病的病理生理起着至关重要的作用。免疫吸附(IA)已被确定为清除自身抗体的有效手段，并导致其他自身抗体相关疾病的临床改善。方法:对178例确诊为新冠肺炎后综合征的患者进行抗体(抗ß1/ß2和抗m3 /M4受体)水平检测，并描述2例抗体水平升高患者接受ia治疗的临床病程。结果:57%(101/178)的新冠肺炎后综合征患者检测到自身抗体。在接受IA治疗的两名患者中，有一名患者自身抗体水平显著降低，临床缓解。然而，该患者在6周内复发，并伴有自身抗体水平升高。结论:综上所述，自身抗体可能在新冠肺炎后发挥病理生理作用，清除自身抗体对部分患者有短暂益处。然而，这些发现应该在随机对照试验中进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Apheresis and Dialysis 医学-泌尿学与肾脏学

CiteScore

3.00

自引率

10.50%

发文量

166

审稿时长

6-12 weeks

期刊介绍： Therapeutic Apheresis and Dialysis is the official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis and the Japanese Society for Dialysis Therapy. The Journal publishes original articles, editorial comments, review articles, case reports, meeting abstracts and Communications information on apheresis and dialysis technologies and treatments.